Neuropsychoimaging of Addictions and Related Conditions Research Program, Icahn School of Medicine at Mount Sinai, Depts. of Psychiatry and Neuroscience, New York, NY, USA; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Neuropsychoimaging of Addictions and Related Conditions Research Program, Icahn School of Medicine at Mount Sinai, Depts. of Psychiatry and Neuroscience, New York, NY, USA; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Neuroscience. 2023 Sep 15;528:102-116. doi: 10.1016/j.neuroscience.2023.07.031. Epub 2023 Aug 9.
Opioid use disorder (OUD) is a major current cause of morbidity and mortality. Long-term exposure to short-acting opioids (MOP-r agonists such as heroin or fentanyl) results in complex pathophysiological changes to neuroimmune and neuroinflammatory functions, affected in part by peripheral mechanisms (e.g., cytokines in blood), and by neuroendocrine systems such as the hypothalamic-pituitary-adrenal (HPA) stress axis. There are important findings from preclinical models, but their role in the trajectory and outcomes of OUD in humans is not well understood. The goal of this narrative review is to examine available data on immune and inflammatory functions in persons with OUD, and to identify major areas for future research. Peripheral blood biomarker studies revealed a pro-inflammatory state in persons with OUD in withdrawal or early abstinence, consistent with available postmortem brain studies (which show glial activation) and diffusion tensor imaging studies (indicating white matter disruptions), with gradual abstinence-associated recovery. The mechanistic roles of these neuroimmune and neuroinflammatory changes in the trajectory of OUD (including recovery and medication management) cannot be examined practically with postmortem data. Collection of longitudinal data in larger-scale human cohorts would allow examination of these mechanisms associated with OUD stage and progression. Given the heterogeneity in presentation of OUD, a precision medicine approach integrating multi-omic peripheral biomarkers and comprehensive phenotyping, including neuroimaging, can be beneficial in risk stratification, and individually optimized selection of interventions for individuals who will benefit, and assessments under refractory therapy.
阿片类使用障碍(OUD)是当前发病率和死亡率的主要原因。长期接触短效阿片类药物(如海洛因或芬太尼等 MOP-r 激动剂)会导致神经免疫和神经炎症功能发生复杂的病理生理变化,部分受外周机制(如血液中的细胞因子)和神经内分泌系统(如下丘脑-垂体-肾上腺(HPA)应激轴)的影响。临床前模型中有重要发现,但它们在人类 OUD 的轨迹和结局中的作用尚不清楚。本综述的目的是检查 OUD 患者免疫和炎症功能的现有数据,并确定未来研究的主要领域。外周血生物标志物研究表明,在戒断或早期戒断期间,OUD 患者存在促炎状态,这与现有的尸检脑研究(显示神经胶质激活)和弥散张量成像研究(表明白质破坏)一致,随着逐渐戒断相关的恢复而逐渐恢复。这些神经免疫和神经炎症变化在 OUD 轨迹(包括恢复和药物管理)中的机制作用不能通过尸检数据进行实际检查。在更大规模的人类队列中收集纵向数据,可以检查与 OUD 阶段和进展相关的这些机制。鉴于 OUD 的表现存在异质性,一种整合多组学外周生物标志物和综合表型(包括神经影像学)的精准医学方法,可有助于风险分层,并为受益的个体选择个体化优化干预措施,并在难治性治疗下进行评估。